Vit B12

PreclinicalSmall molecule

SSitaram Bhartia Institute of Science and Research

Vit B12 is one of 5 small molecule programs targeting Neurodevelopment. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeurodevelopmentCompleted

NeurodevelopmentPreclinical

Completed

Competition

Competitive Landscape

7 competitors in Neurodevelopment

#DrugCompanyPhaseTrials

Medrol

Pfizer

Phase 2

1 2

Rapamune

PPrism Pharmaceuticals

Phase 2

1 3

BPN14770

Shionogi

Phase 2

1 4

Recombinant Human Erythropoietin

Amgen

Preclinical

1 5

Vit B12

SSitaram Bhartia Institute of Science and Research

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ischemic stroke1 trial

The Benefit of Add On DLBS1033 for Ischemic Stroke Patient

Unknown status·—·Phase 2/3·NCT04425590·180 enrolled

Neurodevelopment1 trial

A Comparison of Two Different Doses of Maternal B12 Supplementation in Improving Infant B12 Deficiency and Neurodevelopment

Completed·SSitaram Bhartia Institute of Science and Research·N/A·NCT04083560·708 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Vit B12. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vit B12 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vit B12. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sitaram Bhartia Institute of Science and Research company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSitaram Bhartia Institute of Science and Research

Vit B12

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ischemic stroke1 trial

Neurodevelopment1 trial

References

Drug Info

Quick Facts

Related News